Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Educational needs in the COVID-19 pandemic: a Delphi study among doctors and nurses in Wuhan, China

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. National, clinical cohort study of late effects among survivors of acute lymphoblastic leukaemia: the ALL-STAR study protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Programme theory and realist evaluation of the 'Smoke-Free Vocational Schools' research and intervention project: a study protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Vitamin D levels and the risk of prostate cancer and prostate cancer mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Short-term morbidity and mortality following radical cystectomy: a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To investigate the risk of prostate cancer-specific mortality (PCSM) following initial negative systematic transrectal ultrasound-guided (TRUS) prostate biopsies.

DESIGN: Systematic review.

DATA SOURCES: PubMed and Embase were searched using a string combination with keywords/Medical Subject Headings terms and free text in the search builder. Date of search was 13 April 2020.

STUDY SELECTION: Studies addressing PCSM following initial negative TRUS biopsies. Randomised controlled trials and population-based studies including men with initial negative TRUS biopsies reported in English from 1990 until present were included.

DATA EXTRACTION: Data extraction was done using a predefined form by two authors independently and compared with confirm data; risk of bias was assessed using the Newcastle-Ottawa Scale for cohort studies when applicable.

RESULTS: Four eligible studies were identified. Outcomes were reported differently in the studies as both cumulative incidence and Kaplan-Meier estimates have been used. Regardless of the study differences, all studies reported low estimated incidence of PCSM of 1.8%-5.2% in men with negative TRUS biopsies during the following 10-20 years. Main limitation in all studies was limited follow-up.

CONCLUSION: Only a few studies have investigated the risk of PCSM following initial negative biopsies and all studies included patients before the era of MRI of the prostate. However, the studies point to the fact that the risk of PCSM is low following initial negative TRUS biopsies, and that the level of prostate-specific antigen before biopsies holds prognostic information. This may be considered when advising patients about the need for further diagnostic evaluation.

PROSPERO REGISTRATION NUMBER: CRD42019134548.

Original languageEnglish
JournalBMJ Open
Volume10
Issue number12
Pages (from-to)e040965
ISSN2044-6055
DOIs
Publication statusPublished - 18 Dec 2020

ID: 62033899